Please wait while we open this resource.
K
Clinical reviews
THERAPY OF TYPE 2 DIABETES: MORE GLIFLOZINES AND LESS METFORMIN?
S. Maria della Misericordia Hospital, Perugia, Italy; University of Insubria, Varese, Italy
PDF6 pages2.0 MB
Metformin has long been a cornerstone in the management of Type 2 diabetes due to its glycemic control and cardiovascular risk reduction properties. However, recent studies have shown that gliflozines, a class of drugs that inhibit renal glucose reabsorption, offer significant cardio-renal benefits that may surpass those of metformin. The document reviews various clinical trials that demonstrate the efficacy of gliflozines in reducing cardiovascular events and improving renal outcomes, even in patients without diabetes. It also discusses the differing recommendations from various guidelines regarding the use of these medications in clinical practice.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
ADA Consensus Report: MASLD in People With Diabetes
Same clinical topic · Endocrinology
2025 ADA Diabetes Care Standards Updates
Same clinical topic · Endocrinology
METFORMIN―MECHANISMS OF ITS GLYCEMIA-REDUCING EFFECT
Same clinical topic · Endocrinology
SYNDROME OF INAPPROPRIATE ANTIDIURESIS: FROM PATHOPHYSIOLOGY TO MANAGEMENT
Same clinical topic · Endocrinology
GLYCEMIC EMERGENCIES
Same clinical topic · Endocrinology
DIAGNOSIS AND MANAGEMENT OF CENTRAL DIABETES INSIPIDUS IN ADULTS
Same clinical topic · Endocrinology
ANTI-OBESITY DRUGS: COMPREHENSIVE REVIEW AND EMERGING THERAPIES
Same clinical topic · Endocrinology
DRUG DELIVERY SYSTEMS FOR THYROID DISEASE TREATMENT: A MINI REVIEW ON CURRENT THERAPIES AND ALTERNATIVE APPROACHES
Same clinical topic · Endocrinology
OTHER BENEFITS OF CONTROLLING CARBOHYDRATES
Same clinical topic · Endocrinology